Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis

A case report

Brian J. So, Tanios Bekaii-Saab, Mark A. Bloomston, Tushar C Patel

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Hepatocellular carcinoma is rare, but increasing in prevalence in the United States. Recent studies have shown that sorafenib, a multikinase inhibitor, can reduce tumor progression in patients with this cancer. However, complete remission has not been observed. We report a case of a 78-year old patient with unresectable metastatic hepatocellular carcinoma who had a rapid and complete clinical response following therapy with sorafenib for six months. No evidence of disease recurrence has been noted for 6 months after discontinuation of therapy.

Original languageEnglish (US)
Article number18
JournalJournal of Hematology and Oncology
Volume1
Issue number1
DOIs
StatePublished - 2008
Externally publishedYes

Fingerprint

Hemochromatosis
Hepatocellular Carcinoma
Neoplasms
Recurrence
Therapeutics
sorafenib

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research
  • Molecular Biology
  • Medicine(all)

Cite this

@article{f4509568fcbc4adca129ebd01119e002,
title = "Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report",
abstract = "Hepatocellular carcinoma is rare, but increasing in prevalence in the United States. Recent studies have shown that sorafenib, a multikinase inhibitor, can reduce tumor progression in patients with this cancer. However, complete remission has not been observed. We report a case of a 78-year old patient with unresectable metastatic hepatocellular carcinoma who had a rapid and complete clinical response following therapy with sorafenib for six months. No evidence of disease recurrence has been noted for 6 months after discontinuation of therapy.",
author = "So, {Brian J.} and Tanios Bekaii-Saab and Bloomston, {Mark A.} and Patel, {Tushar C}",
year = "2008",
doi = "10.1186/1756-8722-1-18",
language = "English (US)",
volume = "1",
journal = "Journal of Hematology and Oncology",
issn = "1756-8722",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis

T2 - A case report

AU - So, Brian J.

AU - Bekaii-Saab, Tanios

AU - Bloomston, Mark A.

AU - Patel, Tushar C

PY - 2008

Y1 - 2008

N2 - Hepatocellular carcinoma is rare, but increasing in prevalence in the United States. Recent studies have shown that sorafenib, a multikinase inhibitor, can reduce tumor progression in patients with this cancer. However, complete remission has not been observed. We report a case of a 78-year old patient with unresectable metastatic hepatocellular carcinoma who had a rapid and complete clinical response following therapy with sorafenib for six months. No evidence of disease recurrence has been noted for 6 months after discontinuation of therapy.

AB - Hepatocellular carcinoma is rare, but increasing in prevalence in the United States. Recent studies have shown that sorafenib, a multikinase inhibitor, can reduce tumor progression in patients with this cancer. However, complete remission has not been observed. We report a case of a 78-year old patient with unresectable metastatic hepatocellular carcinoma who had a rapid and complete clinical response following therapy with sorafenib for six months. No evidence of disease recurrence has been noted for 6 months after discontinuation of therapy.

UR - http://www.scopus.com/inward/record.url?scp=72449128320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72449128320&partnerID=8YFLogxK

U2 - 10.1186/1756-8722-1-18

DO - 10.1186/1756-8722-1-18

M3 - Article

VL - 1

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

SN - 1756-8722

IS - 1

M1 - 18

ER -